Simulations Plus Inc

DiBella’s 1,000‑share sale shows routine liquidity, not lost confidence, as Simulations Plus insiders continue buying options amid rising drug‑simulation demand.

Insider buying signals at Simulations Plus Inc. reveal growing confidence as executives purchase shares at zero cost, hinting at potential upside.

Evans Sharlene’s insider buy of 1,776 shares at $0 shows confidence in Simulations Plus, hinting at future upside amid a volatile price decline.